Advances in prostate-specific membrane antigen targeted therapies for prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 547-551, 2010.
Artigo
em Chinês
| WPRIM
| ID: wpr-252785
ABSTRACT
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein, specifically expressed in prostatic epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies for prostate cancer, including immunotherapy, radioimmunotherapy, chemotherapy and gene therapy, and initiated the clinical trials of the first-generation products. However, general clinical application of these therapies still requires extensive clinical studies to test their clinical safety, stability and efficacy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias da Próstata
/
Terapêutica
/
Terapia Genética
/
Radioimunoterapia
/
Glutamato Carboxipeptidase II
/
Tratamento Farmacológico
/
Imunoterapia
/
Antígenos de Superfície
Limite:
Humanos
/
Masculino
Idioma:
Chinês
Revista:
National Journal of Andrology
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS